Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization
SHANGHAI, CHINA, July 20, 2020 – (ACN Newswire) – Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company dedicated
Read More